Chinese Herbal New Drug Tangning Tongluo Tablet Expected to Launch Within 2–3 Years for Type 2 Diabetes Treatment

　　【Pharmaceutical Network Product InformationDiabetes is a chronic metabolic disease. China is a country with a large number of diabetes patients. According to data released by the International Diabetes Federation, as of 2021, the number of diabetes patients in China has reached 141 million, with an incidence rate as high as 12.8%, meaning that one out of every eight people is a diabetes patient. With the increase in the number of diabetes cases in China, the market demand for diabetes drugs is also growing. Data shows that the market size of diabetes drugs in China reached 62.4 billion yuan in 2022 and is expected to reach 132.3 billion yuan by 2030.
 

Currently, the domestic diabetes medication market is mainly dominated by Western medicines from foreign enterprises, such as AstraZeneca's Dapagliflozin Tablets, Novo Nordisk's Semaglutide Injection and Insulin Degludec Injection, MSD's Sitagliptin Phosphate Tablets and Sitagliptin Metformin Hydrochloride Tablets (Ⅱ), with very few traditional Chinese medicine brands. Data from Menet shows that in 2022, the sales of chemical drugs (including biologics) for diabetes treatment in China’s urban physical pharmacies are expected to increase by 12.1%, reaching 11.48 billion yuan. In contrast, the sales scale of traditional Chinese medicine for diabetes treatment has only been around 390 million yuan in the past three years.
 

Facing the diabetes medication market with a scale of billions, Chinese medicine enterprises are actively making efforts. On the evening of February 19, Guizhou Bailing Group Pharmaceutical Co., Ltd. announced that the company had recently received "The Notice on the Acceptance Results of Some Projects from the Special Research Project on Traditional Chinese Medicine Science and Technology for the Year 2021 from the Department of Science and Technology of the National Administration of Traditional Chinese Medicine" (Document No. [2024] 28 of the National TCM Science and Technology Letter). The project titled “Multicenter Clinical Study and Mechanism Exploration of Miao Medicine Tangning Tongluo Tablets in the Prevention and Treatment of Diabetes and Retinopathy Complications” (Project No.: GZY-KJS-2021-006) has been successfully completed and passed the acceptance inspection.
 

The announcement stated that research found Tangning Tongluo Tablets significantly reduced the risk of diabetes onset in prediabetic populations; compared with Calcium Dobesilate Capsules, they more effectively improved corrected vision in patients with non-proliferative diabetic retinopathy (DR) and demonstrated superior efficacy in reducing fundus hemorrhage. Moreover, the safety profile was good, with no serious adverse events reported, providing effective human evidence for the application of a new traditional Chinese medicine.
 

It is reported that DR is one of the diabetic complications with a relatively high incidence rate, posing significant risks, and can even lead to blindness in severe cases, affecting patients' quality of life. Clinical trial results of Tangning Tongluo Tablets have confirmed its clinical value in the treatment of DR, potentially benefiting patients.
 

It is reported that the company will initiate a new drug application next. Guizhou Bailing Group Pharmaceutical Co., Ltd. stated that Tangning Tongluo is expected to apply for direct entry into Phase III clinical trials, and if the progress is smooth, the company aims to achieve new drug market launch within about 2-3 years.
 

Public information shows that Guizhou Bailing Group Pharmaceutical Co., Ltd. is a company with a clear strategic development goal to "strengthen its leading position in the Miao medicine field and strive to become an enterprise with core competitive advantages in the traditional Chinese medicine (TCM) sector." It focuses on implementing the concepts of "Technological Miao Medicine, Cultural Miao Medicine, and Ecological Miao Medicine" as key initiatives, while committing to build a corporate group that owns a full industrial chain in the broader health industry.
 

The third-quarter earnings report of 2023 announced that the company's revenue for the first three quarters of 2023 was approximately 2.81 billion yuan, representing a year-on-year increase of 33.88%. The net profit attributable to shareholders of the listed company was about 140 million yuan, marking a year-on-year increase of 40.21%. The basic earnings per share were 0.1 yuan, reflecting a year-on-year increase of 42.86%.
 

By the close of trading on February 19, 2024, Guizhou Bailing Group Pharmaceutical Co., Ltd. closed at RMB 7.48, down 1.06%, with a turnover rate of 1.69%, a trading volume of 206,900 shares, and a turnover of RMB 155 million.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.